Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations

被引：0
|
作者：
Cardenal, Felipe [2 ]
Moran, Teresa [1 ]
Queralt, Cristina [1 ]
Porta, Ruth [3 ]
Camps, Carlos [4 ]
Majem, Margarita [5 ]
Lopez-Vivanco, Guillermo [6 ]
Isla, Dolores [7 ]
Provencio, Mariano [8 ]
Sanchez, Jose Javier [9 ]
Taron, Miquel [1 ]
Rosell, Rafael [1 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[2] Hosp Duran & Reynals, Catalan Inst Oncol, Bellvitge, Spain
[3] Hosp Trueta, Girona, Spain
[4] Hosp Gen Valencia, Valencia, Spain
[5] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[6] Hosp Cruces, Cruces Baracaldo, Spain
[7] Hosp Lozano Blesa, Zaragoza, Spain
[8] Hosp Puerta de Hierro, Madrid, Spain
[9] Autonomous Univ Madrid, E-28049 Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S324 / S325
页数：2
相关论文
共 50 条
  • [1] PHASE II MULTICENTER TRIAL OF ERLOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Isobe, Kazutoshi
    Homma, Sakae
    Takahashi, Kazuhisa
    Koyama, Ryo
    Mori, Kiyoshi
    Kasai, Takashi
    Tominaga, Shigeru
    Kido, Kenji
    Takaya, Hisashi
    Kishi, Kazuma
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1165 - S1166
  • [2] Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Provencio, M.
    Camps, C.
    Isla, D.
    Gonzalez-Larriba, J.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Domingues, Pedro Masson
    Montella, Tatiane
    Baldotto, Clarissa Serodio
    Siqueira, Mariana
    Zukin, Mauro
    Ferreira, Carlos Gil
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S169 - S169
  • [4] Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    O'Leary, Connor
    Gasper, Harry
    Sahin, Katherine B.
    Tang, Ming
    Kulasinghe, Arutha
    Adams, Mark N.
    Richard, Derek J.
    O'Byrne, Ken J.
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
  • [5] Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
    Normanno, Nicola
    Denis, Marc G.
    Thress, Kenneth S.
    Ratcliffe, Marianne
    Reck, Martin
    ONCOTARGET, 2017, 8 (07) : 12501 - 12516
  • [6] Clinical Outcomes in Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring Rare Epidermal Growth Factor Receptor (EGFR) Mutations
    Domingues, Pedro M.
    Montella, Tatiane
    Zukin, Mauro
    Baldotto, Clarissa
    Ferreira, Carlos
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S206 - S207
  • [7] VARIABILITY OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN SERUM DURING ERLOTINIB THERAPY AND ITS CLINICAL IMPLICATIONS: EXPLORATORY ANALYSIS OF A PHASE II STUDY OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATIONS
    Maemondo, Makoto
    Nishio, Makoto
    Yamamoto, Noboru
    Chikamori, Kenichi
    Katakami, Nobuyuki
    Hida, Toyoaki
    Seto, Takashi
    Yoshioka, Hiroshige
    Kozuki, Toshiyuki
    Ohishi, Norihisa
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S384 - S385
  • [8] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [9] Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial
    Massuti, B.
    Moran, T.
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Camps, C.
    Majem, M.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    CANCER RESEARCH, 2006, 66 (08)
12345